The role of oxidative and nitrosative stress in accelerated aging and major depressive disorder

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 65, Issue , 2016, Pages 134-144

  Maurya, Pawan Kumar ^a,b   Noto, Cristiano ^a   Rizzo, Lucas B ^a,c   Rios, Adiel C ^a   Nunes, Sandra O V ^d   Barbosa, Décio Sabbatini ^d   Sethi, Sumit ^a   Zeni, Maiara ^a   Mansur, Rodrigo B ^e   Maes, Michael ^d,f   Brietzke, Elisa ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b AMITY UNIVERSITY   (India)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d STATE UNIVERSITY OF LONDRINA   (Brazil)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Accelerated aging; Clinical implications; Major depressive disorder; Oxidative stress

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ARYLDIALKYLPHOSPHATASE 1; ASCORBIC ACID; BIOLOGICAL MARKER; CATALASE; CURCUMIN; GLUTATHIONE; GLUTATHIONE PEROXIDASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MALONALDEHYDE; NITRIC OXIDE; OMEGA 3 FATTY ACID; PLACEBO; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; UBIDECARENONE; ZINC;

AGING; ANTIDEPRESSANT ACTIVITY; ANTIOXIDANT ACTIVITY; CALORIC RESTRICTION; DEPRESSION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; HUMAN; KINESIOTHERAPY; LIFESTYLE; LIPID PEROXIDATION; MAJOR DEPRESSION; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; THERAPY EFFECT; ANIMAL; METABOLISM; PHYSIOLOGY;

AGING; ANIMALS; BIOMARKERS; DEPRESSIVE DISORDER, MAJOR; HUMANS; OXIDATIVE STRESS;

EID: 84942342655     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2015.08.016     Document Type: Review

References (210)

1. Al-Hakeim H.K., Al-Rammahi D.A., Al-Dujaili A.H. IL-6, IL-18, sIL-2R, and TNFα proinflammatory markers indepressionand schizophrenia patients who are free of overtinflammation. J. Affect. Disord. 2015, 182:106-114.
2. Ali S.H., Madhana R.M. K V a, kasala. ER, bodduluru LN, pitta S, et al. Resveratrolamelioratesdepressive-like behavior in repeated corticosterone-induceddepressionin mice. Steroids 2015, 101:37-42.
3. Allen J.S., Bruss J., Brown C.K., Damasio H. Normalneuroanatomicalvariationdue toage: themajorlobesand aparcellationof thetemporalregion. Neurobiol. Aging 2005, 26(9):1245-1260.
4. Ames B.N., Shigenaga M.K., Gold L.S. DNA lesions, inducible DNA repair, and cell division: three key factors in mutagenesis and carcinogenesis. Environ. Health Perspect. 1993, 101(Suppl. 5):35-44.
5. Anderson G., Maes M. Neurodegeneration in Parkinson's disease: interactions ofoxidativestress, tryptophan catabolites anddepressionwith mitochondria and sirtuins. Mol. Neurobiol. 2014, 49(2):771-783.
6. Anderson R.M., Shanmuganayagam D., Weindruch R. Caloric restriction and aging: studies in mice and monkeys. Toxicol. Pathol. 2009, 37(1):47-51.
7. Andreux P.A., Houtkooper R.H., Auwerx J. Pharmacological approaches to restore mitochondrial function. Nat. Rev. Drug Discov. 2013, 12(6):465-483.
8. Apicella E. Depressionand immunity: the HCV model. Psychiatr. Danub. 2014, 26(Suppl. 1):132-137.
9. Aubert G., Lansdorp P.M. Telomere and aging. Physiol. Rev. 2008, 88:557-579.
10. Azevedo Da Silva M., Singh-Manoux A., Brunner E.J., Kaffashian S., Shipley M.J., Kivimaki M., et al. Bidirectional association between physical activity and symptoms of anxiety and depression: the Whitehall II study. Eur. J. Epidemiol. 2012, 27:537-546.
11. Bahramsoltani R., Farzaei M.H., Farahani M.S., Rahimi R. Phytochemical constituents as future antidepressants: a comprehensive review. Rev. Neurosci. 2015, (In press).
12. Barber A.A., Bernheim F. Lipidperoxidation: its measurement, occurrence, and significance in animal tissues. Adv. Gerontol. Res. 1967, 2:355-403.
13. Barim A.O., Aydin S., Colak R., Dag E., Deniz O., Sahin I. Ghrelin, paraoxonaseand arylesterase levels indepressivepatients before and after citalopram treatment. Clin. Biochem. 2009, 42(10-11):1076-1081.
14. Berk M., Kapczinski F., Andreazza A.C., Dean O.M., Giorlando F., Maes M., et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci. Biobehav. Rev. 2011, 35:804-817.
15. Berk M., Copolov D.L., Dean O., Lu K., Jeavons S., Schapkaitz I., et al. N-acetyl cysteine for depressive symptoms in bipolar disorder-a double-blind randomized placebo-controlled trial. Biol. Psychiatry 2008, 64(6):468-475.
16. Berk M., Dean O.M., Cotton S.M., Jeavons S., Tanious M., Kohlmann K., et al. The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial. J. Clin. Psychiatry 2014, 75(6):628-636.
17. Berk M., Malhi G.S., Gray L.J., Dean O.M. The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol. Sci. 2013, 34(3):167-177.
18. Black C.N., Bot M., Scheffer P.G., Cuijpers P., Penninx B.W. Is depression associated with increased oxidative stress? A system review and meta-analysis. Psychoneuroendocrinology 2015, 51:164-175.
19. Bloch M.H., Hannestad J. Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Mol. Psychiatry 2012, 17(12):1272-1282.
20. Bortolasci C.C., Maes M., Vargas H.O., Souza-Nogueira A., Moreira E.G., Nunes S.O., et al. Paraoxonase 1 status and interactions between Q192R functional genotypes by smoking contribute significantly to total plasma radical trapping antioxidant potential. Neurosci. Lett. 2014, 581:46-51.
21. Bortolasci C.C., Vargas H.O., Vargas Nunes S.O., de Melo L.G., de Castro M.R., Moreira E.G., et al. Factors influencing insulin resistance in relation to atherogenicity in mood disorders, the metabolic syndrome. J. Affect. Disord. 2015, 179:148-155.
22. Brietzke E., Stertz L., Fernandes B.S., Kauer-Sant'anna M., Mascarenhas M. Escosteguy VargasA, etal.Comparisonofcytokinelevelsindepressed, manicandeuthymicpatientswithbipolardisorder. J. Affect. Disord. 2009, 116(3):214-217.
23. Brody S. High-dose ascorbic acid increases intercourse frequency and improves mood: a randomized controlled clinical trial. Biol. Psychiatry 2002, 52(4):371-374.
24. Brown S. Excess mortality of schizophrenia. Meta Anal. Br. J. Psychiatry 1997, 171:502-508.
25. Cawthon R.M., Smith K.R., O'Brien E., Sivatchenko A., Kerber R.A. Association between telomere length in blood and mortality in people aged 60years or older. Lancet 2003, 361(9355):393-395.
26. Cefalu C.A. Theoriesand mechanisms ofaging. Clin. Geriatr. Med. 2011, 27(4):491-506.
27. Chandler-Laney P.C., Castaneda E., Pritchett C.E., Smith M.L., Giddings M., Artiga A.I., et al. A history of caloric restriction induces neurochemical and behavioral changes in rats consistent with models of depression. Pharmacol. Biochem. Behav. 2007, 87(1):104-114.
28. Chelikani P., Fita I., Loewen P.C. Diversity of structures and properties among catalases. Cell. Mol. Life Sci. 2004, 61(2):192-208.
29. Cherki M., Berrougui H., Isabelle M., Cloutier M., Koumbadinga G.A., Khalil A. Effect of PON1 polymorphism on HDL antioxidant potential is blunted with aging. Exp. Gerontol. 2007, 42:815-824.
30. Choi S.Y., Li J., Jo S.H., Lee S.J., Oh S.B., Kim J.S., et al. Desipramine inhibits Na+/H+ exchanger in human submandibular cells. J. Dent. Res. 2006, 85(9):839-843.
31. Christensen K., Doblhammer G., Rau R., Vaupel J.W. Ageing populations: the challenges ahead. Lancet 2009, 374:1196-1208.
32. Cocchi P., Silenzi M., Calabri G., Salvi G. Antidepressant effect of vitamin C. Pediatrics 1980, 65(4):862-863.
33. Cohen B.E., Edmondson D., Kronish I.M. State of the art review: depression, stress, anxiety, andcardiovascular disease. Am. J. Hypertens. 2015, (pii:hpv047).
34. Conn V.S. Depressive symptom outcomes of physical activity interventions: meta-analysis findings. Ann. Behav. Med. 2010, 39:128-138.
35. Corp S.A., Gitlin M.J., Altshuler L.L. Areviewof the use of stimulants and stimulant alternatives in treating bipolardepressionand major depressive disorder. J. Clin. Psychiatry 2014, 75(9):1010-1018.
36. Counter C.M., Avilion A.A., LeFeuvre C.E., Stewart N.G., Greider C.W., Harley C.B., et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 1992, 11(5):1921-1929.
37. Crimmins E.M., Beltrán-Sánchez H. Mortality and morbidity trends: is there compression of morbidity?. J. Gerontol. B. Psychol. Sci. Soc. Sci. 2011, 66(1):75-86.
38. Crispín-Trebejo B., Robles-Cuadros M.C., Bernabé-Ortiz A. Association betweendepressionand glycemic control among type 2diabetespatients in lima. Peru. Asia Pac Psychiatry 2015, 10.1111/appy.12190.
39. Csiszar A., Gautam T., Sosnowska D., Tarantini S., Banki E., Tucsek Z., et al. Caloric restriction confers persistent anti-oxidative, pro-angiogenic, and anti-inflammatory effects and promotes anti-aging miRNA expression profile in cerebromicrovascular endothelial cells of aged rats. Am J. Physiol. Heart Circ. Physiol. 2014, 307(3):H292-H306.
40. Cuijpers P., Smit F. Excessmortalityin depression: a meta-analysis of community studies. J. Affect. Disord. 2002, 72(3):227-236.
41. Das K.C., Muniyappa H. Age-dependent mitochondrial energy dynamics in the mice heart: role ofsuperoxide dismutase-2. Exp. Gerontol. 2013, 48(9):947-959.
42. Das S.K., Gilhooly C.H., Golden J.K., Pittas A.G., Fuss P.J., Cheatham R.A., et al. Long-term effects of 2 energy-restricted diets differing in glycemic load on dietary adherence, body composition, and metabolism in CALERIE: a 1-y randomized controlled trial. Am. J. Clin. Nutr. 2007, 5(4):1023-1030.
43. Del Pozo-Cruz J., Rodríguez-Bies E., Ballesteros-Simarro M., Navas-Enamorado I., Tung B.T., Navas P., et al. Physical activity affects plasmacoenzyme Q10levels differently in young and old humans. Biogerontology 2014, 15(2):199-211.
44. Dean O.M., Maes M., Ashton M., Berk L., Kanchanatawan B., Sughondhabirom A., et al. Protocol and rationale - the efficacy of minocycline as an adjunctive treatment for major depressive disorder: a double blind, randomised, placebo controlled trial. Clin. Psychopharmacol. Neurosci. 2014, 12(3):180-188.
45. Donato A.J., Walker A.E., Magerko K.A., Bramwell R.C., Black A.D., Henson G.D., et al. Life-long caloric restriction reduces oxidative stress and preserves nitric oxide bioavailability and function in arteries of old mice. Aging Cell 2013, 12(5):772-783.
46. Dröge W. Oxidative stress and aging. Adv. Exp. Med. Biol. 2003, 543:191-200.
47. Dunn E.C., Brown R.C., Dai Y., Rosand J., Nugent N.R., Amstadter A.B., et al. Geneticdeterminants ofdepression: recent findings and future directions. Harv. Rev. Psychiatry 2015, 23(1):1-18.
48. Durrington P.N., Mackness B., Mackness M.I. Paraoxonase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2001, 21:473-480.
49. Fajemiroye J.O., Polepally P.R., Chaurasiya N.D., Tekwani B.L., Zjawiony J.K., Costa E.A. Oleanolic acid acrylate elicitsantidepressant-like effect mediated by 5-HT1A receptor. Sci. Report. 2015, 5:11582.
50. Fischer C.W., Eskelund A., Budac D.P., Tillmann S., Liebenberg N., Elfving B., et al. Interferon-alpha treatment induces depression-like behavior accompanied by elevated hippocampal quinolinic acid levels in rats. Behav. Brain Res. 2015, 293:166-172.
51. Fontana L., Klein S. Aging, adiposity, and calorie restriction. JAMA 2007, 297(9):986-994.
52. Fontana L., Partridge L., Longo V.D. Extending healthy life span - from yeast to humans. Science 2010, 328:321-326.
53. Forlenza M.J., Miller G.E. Increased serum levels of 8-hydroxy-2'-deoxyguanosine in clinicaldepression. Psychosom. Med. 2006, 68(1):1-7.
54. Gałecki P., Florkowski A., Mrowicka M., Pietras T., Gałecka E. Calcium ions, glutaminate acid, hypothalamic-pituitary-adrenal axis, calcium dependent ATP-ase as causes of oxidative damage in depression patients (part II). Pol. MerkurLekarski 2008, 24(139):72-75.
55. Galecki P., Szemraj J., Bienkiewicz M., Zboralski K., Galecka E. Oxidative stress parameters after combined fluoxetine and acetylsalicylic acid therapy in depressive patients. Humanist. Psychol. 2009, 24:277-286.
56. Garrido-Maraver J., Cordero M.D., Oropesa-Avila M., Vega A.F., de la Mata M., Pavon A.D., et al. Clinical applications ofcoenzyme Q10. Front. Biosci. (Landmark Ed) 2014, 19:619-633.
57. Gawryluk J.W., Wang J.F., Andreazza A.C., Shao L., Young L.T. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int. J. Neuropsychopharmacol. 2011, 14(1):123-130.
58. Giordano E., Visioli F. Long-chain omega 3 fatty acids: molecular bases of potential antioxidant actions. Prostaglandins Leukot. Essent. Fat. Acids 2014, 90(1):1-4.
59. Glei D., Mesle F., Vallin J. Diverging trends in life expectancy at age 50: a look at causes of death. International Differences in Mortality at Older Ages: Dimensions and Sources 2010, The National Academies Press, Washington, DC. E.M. Crimmins, S.H. Preston, B. Cohen (Eds.).
60. Godlewska B.R., Near J., Cowen P.J. Neurochemistry of majordepression: a study using magnetic resonance spectroscopy. Psychopharmacology 2015, 232(3):501-507.
61. Granzotto A., Sensi S.L. Intracellular zinc is a critical intermediate in the excitotoxic cascade 2015, Neurobiol, Dis. 10.1016/j.nbd.2015.04.010.
62. Gu F., Chauhan V., Chauhan A. Glutathioneredox imbalance in brain disorders. Curr. Opin. Clin. Nutr. Metab. Care 2015, 18(1):89-95.
63. Gutteridge J.M., Halliwell B. Free radicals and antioxidants in the year 2000.A historical look to the future. Ann. N. Y. Acad. Sci. 2000, 899:136-147.
64. Harley C.B., Futcher A.B., Greider C.W. Telomeres shorten during ageing of human fibroblasts. Nature 1990, 345:458-460.
65. Harman D. Free radical theory of aging: an update: increasing the functional life span. Ann. N. Y. Acad. Sci. 2006, 1067:10-21.
66. Harman D. Origin and evolution of the free radical theory ofaging: a brief personal history, 1954-2009. Biogerontology 2009, 10(6):773-781.
67. Hartmann N., Boehner M., Groenen F., Kalb R. Telomerelengthofpatientswithmajor depressionisshortenedbutindependentfromtherapyandseverityof the disease. Depress Anxiety 2010, 27(12):1111-1116.
68. Hazari N., Bhad R. Kynurenine pathway (KP) inhibitors: novelagentsfor the management of depression. J. Psychopharmacol. 2015, (In press).
69. Henle E.S., Han Z., Tang N., Rai P., Luo Y., Linn S. Sequence-specific DNA cleavage by Fe2+-mediated Fenton reactions has possible biological implication. J. Biol. Chem. 1999, 274(2):962-971.
70. Hidaka B.H. Depression as a disease of modernity: explanations for increasing prevalence. J. Affect. Disord. 2012, 140:205-214.
71. Hughes B. FDA drug approval. Nature Rev. 2010, 9:89-92.
72. Huffman J.C., Celano C.M. Depressionincardiovascular disease: from awareness to action. Trends Cardiovasc. Med. 2015, 10.1016/j.tcm.2015.02.007.
73. Iida T., Chikamura C., Inoue K., Ito Y., Ishikawa H., Teradaira R., et al. Association of STAI and SDS scores with8-hydroxydeoxyguanosineand serotonin levels in young women withdepressivesymptoms. J. Neuropsychiatr. Clin. Neurosci. 2011, 23(1).
74. Ikram M.A., Vrooman H.A., Vernooij M.W., van der Lijn F., Hofman A., van der Lugt A., et al. Brain tissue volumes in the general elderly population. The Rotterdam scan study. Neurobiol. Aging 2008, 29(6):882-890.
75. Inal M.E., Kanbak G., Sunal E. Antioxidant enzyme activities and malondialdehyde levels related to aging. Clin. Chim. Acta 2001, 305(1-2):75-80.
76. Jayasekara R., Procter N., Harrison J., Skelton K., Hampel S., Draper R., et al. Cognitive behavioral therapy for older adults withdepression: areview. J. Ment. Health 2014, 30:1-4.
77. Katon W., Pedersen H.S., Ribe A.R., Fenger-Grøn M., Davydow D., Waldorff F.B., et al. Effect ofdepressionand diabetes mellitus on the risk fordementia: a national population-based cohort study. JAMA Psychiatry 2015, 72(6):612-619.
78. Kessing L.V., Andersen P.K. Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder?. J. Neurol. Neurosurg. Psychiatry 2004, 75:1662-1666.
79. Klinedinst N.J. Regenold WT.A mitochondrial bioenergetic basis ofdepression. J. Bioenerg. Biomembr. 2015, 47(1-2):155-171.
80. Kodydková J., Vávrová L., Zeman M., Jirák R., Macásek J., Stanková B., et al. Antioxidative enzymes and increased oxidative stress indepressivewomen. Clin. Biochem. 2009, 42(13-14):1368-1374.
81. Kotan V.O., Sarandol E., Kirhan E., Ozkaya G., Kirli S. Effects of long-term antidepressant treatment on oxidative status in major depressive disorder: a 24-week follow-up study. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2011, 35(5):1284-1290.
82. Krogh J., Nordentoft M., Sterne J.A., Lawlor D.A. The effect of exercise in clinically depressed adults: systematic review and meta-analysis of rando-mized controlled trials. J. Clin. Psychiatry 2011, 72:529-538.
83. Kuloglu M., Atmaca M., Tezcan E., Gecici O., Tunckol H., Ustundag B. Antioxidant enzyme activities and malondialdehyde levels in patients with obsessive-compulsivedisorder. Neuropsychobiology 2002, 46(1):27-32.
84. Kumar D., Rizvi S.I. Plasma paraoxonase1arylesterase activity in D-galactose-induced aged rat model: correlation with LDL oxidation and redox status. Aging Clin. Exp. Res. 2014, 26(3):261-267.
85. Kumar P., Maurya P.K. Epigallocatechin-3-gallate protects erythrocyte Ca(2+)-ATPase and Na(+)/K(+)-ATPase against oxidative induced damage during aging in humans. Adv. Pharm. Bull 2014, 4(Suppl. 1):443-447.
86. Kumar P., Maurya P.K. L-cysteine efflux in erythrocytes as a function of human age: correlation with reduced glutathione and total anti-oxidant potential. Rejuvenation Res. 2013, 16(3):179-184.
87. Kumar P., Chand S. Maurya PK 2015, Influence of dietary capsacin on redox regulation in red blood cells during human aging, Adv Pharm Bull, (In press).
88. Kurup A.R., Kurup P.A. MembraneNa(+)-K+ATPasemediated cascade in bipolar mooddisorder, majordepressivedisorder, and schizophrenia--relationship to hemispheric dominance. Int. J. Neurosci. 2002, 112(8):965-982.
89. La Du B.N. Structural and functional diversity of paraoxonases. Nat. Med. 1996, 2:1186-1187.
90. Lai J., Moxey A., Nowak G., Vashum K., Bailey K., McEvoy M. The efficacy of zinc supplementation in depression: systematic review of randomised controlled trials. J. Affect. Disord. 2012, 136(1-2):e31-e39.
91. Lapidus K.A., Gabbay V., Mao X., Johnson A., Murrough J.W., Mathew S.J., et al. In vivo (1)H MRS study of potential associations between glutathione, oxidative stress and anhedonia inmajor depressive disorder. Neurosci. Lett. 2014, 569:74-79.
92. Le Bourg E. Evolutionarytheoriesofagingcan explain why we age. Interdiscip. Top. Gerontol. 2014, 39:8-23.
93. Leonard B., Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci. Biobehav. Rev. 2012, 36(2):764-785.
94. Lesperance F., Frasure-Smith N., St-Andre E., Turecki G., Lesperance P., Wisniewski S.R. The efficacy of omega-3 supplementation for major depression: a randomized controlled trial. J. Clin. Psychiatry 2011, 72(8):1054-1062.
95. Li Q., Verma I.M. NF-kappaB regulation in the immune system. Nat. Rev. Immunol 2002, 2(10):725-734.
96. Li F.C., Tseng H.P., Chang A.Y. Neuroprotective role ofcoenzyme Q10against dysfunction of mitochondrial respiratory chain at rostral ventrolateral medulla during fatal mevinphos intoxication in the rat. Ann. N. Y. AcadSci 2005, 1042:195-202.
97. Lindqvist D., Epel E.S., Mellon S.H., Penninx B.W., Révész D., Verhoeven J.E., et al. Psychiatric disorders and leukocyte telomere length: underlying mechanisms linking mental illness with cellularaging. Neurosci. Biobehav. Rev. 2015, 55:333-364.
98. Lobato K.R., Cardoso C.C., Binfare R.W., Budni J., Wagner C.L., Brocardo P.S. Alpha-tocopherol administration produces an antidepressant-like effect in predictive animal models of depression. Behav. Brain Res. 2010, 209(2):249-259.
99. Logan R.W., Edgar N., Gillman A.G., Hoffman D., Zhu X., McClung C.A. Chronic stress induces brain region-specific alterations of molecular rhythms that correlate with depression-like behavior in mice. Biol. Psychiatry 2015, 10.1016/j.biopsych.2015.01.011.
100. Lopresti A.L., Maes M., Maker G.L., Hood S.D., Drummond P.D. Curcumin for the treatment of major depression: a randomised, double-blind, placebo controlled study. J. Affect. Disord. 2014, 167:368-375.
101. Lopresti A.L., Maker G.L., Hood S.D., Drummond P.D. A review of peripheral biomarkers in major depression: the potential of inflammatory and oxidative stress biomarkers. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2014, 48:102-111.
102. Lorenz M., Saretzki G., Sitte N., Metzkow S., von Zglinicki T. BJ fibroblasts display high antioxidant capacity and slow telomere shortening independent of hTERT transfection. Free Radic. Biol. Med. 2001, 31:824-831.
103. Lundberg J.O., Weitzberg E. NO synthase independent NO generation in mammals. Biochem. Biophys. Res. Commun. 2010, 396(1):39-45.
104. Lundin A., Modig K., Halldin J., Carlsson A.C., Wändell P., Theobald H. Mentaldisorderand long-term risk ofmortality: 41years of follow-up of a population sample in Stockholm, Sweden. Epidemiol. Psychiatry Sci. 2015, 1:1-9.
105. Maes M., Anderson G., Kubera M., Berk M. Targeting classical IL-6 signalling or IL-6 trans-signalling indepression?. Expert Opin. Ther. Targets 2014, 18(5):495-512.
106. Maes M., Galecki P., Chang Y.S., Berk M. A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro) degenerative processes in that illness. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2011, 35:676-692.
107. Maes M., Mihaylova I., Kubera M., Uytterhoeven M., Vrydags N., Bosmans E. Lower whole blood glutathione peroxidase (GPX) activity in depression, but not in myalgic encephalomyelitis/chronic fatigue syndrome: another pathway that may be associated with coronary artery disease and neuroprogression in depression. Neuroendocrinol. Lett. 2011, 32:133-140.
108. Maes M., Mihaylova I., Kubera M., Uytterhoeven M., Vrydags N., Bosmans E. Lower plasmacoenzyme Q10indepression: a marker for treatment resistance and chronic fatigue indepression and a risk factor to cardiovasculardisorderin that illness. Neuro. Endocrinol. Lett. 2009, 30(4):462-469.
109. Maes M., De Vos N., Pioli R., Demedts P., Wauters A., Neels H., et al. Lower serum vitamin E concentrations in major depression. Another marker of lowered antioxidant defenses in that illness. J. Affect. Disord. 2000, 58(3):241-246.
110. Maes M., Fisar Z., Medina M., Scapagnini G., Nowak G., Berk M. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology 2012, 20(3):127-150.
111. Maes M., Kubera M., Mihaylova I., Geffard M., Galecki P., Leunis J.C., et al. Increased autoimmune responses against auto-epitopes modified by oxidative and nitrosative damage in depression: implications for the pathways to chronic depression and neuroprogression. J. Affect. Disord. 2013, 149(1-3):23-29.
112. Maes M., Mihaylova I., Leunis J.C. Chronic fatigue syndrome is accompanied by an IgM-related immune response directed against neopitopes formed by oxidative or nitrosative damage to lipids and proteins. Neuro. Endocrinol. Lett. 2006, 27(5):615-621.
113. Magalhães P.V., Dean O.M., Bush A.I., Copolov D.L., Malhi G.S., Kohlmann K., et al. N-acetylcysteine for major depressive episodes in bipolar disorder. Rev. Bras. Psiquiatr. 2011, 33(4):374-378.
114. Malykhin N.V., Coupland N.J. Hippocampal neuroplasticity in majordepressive disorder. Neuroscience 2015, 10.1016/j.neuroscience.2015.04.047.
115. Maruyama W., Shaomoto-Nagai M., Kato Y., Hisaka S., Osawa T., Naoi M. Role oflipidperoxide in the neurodegenerative disorders. Subcell. Biochem. 2014, 77:127-136.
116. Maurya PK, Prakash S. Intracellular uptake of (-)epicatechin by human erythrocytes as a function of human age. Phytother. Res. 2011; 25(6):944-6.
117. Maurya P.K., Rizvi S.I. Protective role of tea catechins on erythrocytes subjected to oxidative stress during human aging. Nat. Prod. Res. 2009, 23(12):1072-1079.
118. Maurya P.K., Kumar P., Siddiqui N., Tripathi P., Rizvi S.I. Age-associated changes in erythrocyte glutathione peroxidase activity: correlation with total antioxidant potential. Indian J. Biochem. Biophys. 2010, 47(5):319-321.
119. McIntyre R.S., Soczynska J.K., Konarski J.Z., Woldeyohannes H.O., Law C.W., Miranda A., et al. Should depressive syndromes be reclassified as "metabolic syndrome type II"?. Ann. Clin. Psychiatry 2007, 19:257-264.
120. Michel T.M., Pülschen D., Thome J. The role ofoxidative stressindepressivedisorders. Curr. Pharm. Des. 2012, 18(36):5890-5899.
121. Miyaoka T., Wake R., Furuya M., Liaury K., Ieda M., Kawakami K., et al. Minocycline as adjunctive therapy for patients with unipolar psychotic depression: an open-label study. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2012, 37(2):222-226.
122. Miller M.W., Sadeh N. Traumaticstress, oxidative stressand post-traumaticstressdisorder: neurodegeneration and the accelerated-aginghypothesis. Mol. Psychiatry 2014, 19(11):1156-1162.
123. Morales-Suárez-Varela M., Llopis-González A., González-Albert V., López-Izquierdo R., González-Manzano I., Cháves J., et al. Correlationofzincwithoxidative stressbiomarkers. Int. J. Environ. Res. Public Health 2015, 12(3):3060-3076.
124. Morris G., Anderson G., Dean O., Berk M., Galecki P., Martin-Subero M., et al. Theglutathionesystem: a new drug target in neuroimmune disorders. Mol. Neurobiol. 2014, 50(3):1059-1084.
125. Moylan S., Berk M., Dean O.M., Samuni Y., Williams L.J., O'Neil A., et al. Oxidative&nitrosativestressindepression: whysomuchstress?. Neurosci. Biobehav. Rev. 2014, 45:46-62.
126. Moylan S., Maes M., Wray N.R., Berk M. The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol. Psychiatry 2013, 18(5):595-606.
127. Musselman D.L., Evans D.L., Nemeroff C.B. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch. Gen. Psychiatry 1998, 55:580-592.
128. Naik S.R., Thakare V.N., Patil S.R. Protective effect of curcumin on experimentally induced inflammation, hepatotoxicity and cardiotoxicity in rats: evidence of its antioxidant property. Exp. Toxicol. Pathol. 2011, 63(5):419-431.
129. Németh I., Orvos H., Boda D. Bloodglutathioneredox status in gestational hypertension. Free Radic. Biol. Med. 2001, 30(7):715-721.
130. Nguyen D.S., Sok D.E. Oxidative inactivation of paraoxonase 1, an antioxidant protein and its effect on antioxidant action. Free Radic. Res. 2003, 37:1319-1330.
131. Nowak G. Zinc, future mono/adjunctive therapy fordepression: mechanisms of antidepressant action. Pharmacol. Rep. 2015, 67(3):659-662.
132. Nowak G., Siwek M., Dudek D., Zieba A., Pilc A. Effect of zinc supplementation on antidepressant therapy in unipolar depression: a preliminary placebo-controlled study. Pol. J. Pharmacol. 2003, 55(6):1143-1147.
133. Nunes S.O., Vargas H.O., Prado E., Barbosa D.S., de Melo L.P., Moylan S., et al. The shared role of oxidative stress and inflammation in major depressive disorder and nicotine dependence. Neurosci. Biobehav. Rev. 2013, 37:1336-1345.
134. Nunes S.O.V., de Melo L.G.P., de Castro M.R.P., Barbosa D.S., Vargas H.O., Berk M., et al. Atherogenic index of plasma and atherogenic coefficient are increased in major depression and bipolar disorder, especially when comorbid with tobacco use disorder. J. Affect. Disord. 2015, 172:55-62.
135. Nunomura A., Tamaoki T., Motohashi N. Role ofoxidative stressin the pathophysiology of neuropsychiatricdisorders. Seishin Shinkeigaku Zasshi 2014, 116(10):842-858.
136. Nuttall F.Q., Almokayyad R.M., Gannon M.C. Comparison of a carbohydrate-free diet vs. fasting on plasma glucose, insulin and glucagon in type 2 diabetes. Metabolism 2015, 64(2):253-262.
137. O'Brien S.M., Scully P., Fitzgerald P., Scott L.V., Dinan T.G. Plasmacytokineprofilesindepressedpatientswhofailtorespondtoselectiveserotoninreuptakeinhibitor therapy. J. Psychiatr. Res. 2007, 41(3-4):326-331.
138. Olovnikov A.M. A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. J. Theor. Biol. 1973, 41(1):181-190.
139. Ott C., Jacobs K., Haucke E., Navarrete Santos A., Grune T., et al. Role of advanced glycation end productsincellular signaling. Redox Biol. 2014, 2:411-429.
140. Palta P., Samuel L.J., Miller E.R., Szanton S.L. Depression and oxidative stress: results from meta-analysis of observational studies. Psychosom. Med. 2014, 74(1):12-19.
141. Pamplona R., Barja G. Mitochondrial oxidative stress, aging and caloric restriction: the protein and methionine connection. Biochim. Biophys. Acta 2006, 1757(5-6):496-508.
142. Pandey K.B., Rizvi S.I. Resveratrol up-regulates the erythrocyte plasma membrane redox system and mitigates oxidation-induced alterations in erythrocytes during aging in humans. Rejuvenation Res. 2013, 16(3):232-240.
143. Pandya C.D., Howell K.R., Pillai A. Antioxidants as potential therapeutics for neuropsychiatric disorders. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2013, 46:214-223.
144. Pasic J., Levy W.C., Sullivan M.D. Cytokinesindepressionand heart failure. Psychosom. Med. 2003, 65(2):181-193.
145. Penninx B.W., Geerlings S.W., Deeg D.J., van Eijk J.T., van Tilburg W., Beekman A.T. Minor and major depression and the risk of death in older persons. Arch. Gen. Psychiatry 1999, 56(10):889-895.
146. Perez-Cornago A., Lopez-Legarrea P. de laIglesia R, lahortiga F, Martinez JA, zulet MA. Longitudinal relationship of diet and oxidative stress with depressive symptoms in patients with metabolic syndrome after following a weight loss treatment: the RESMENA project. Clin. Nutr. 2014, 33(6):1061-1067.
147. Persson N., Ghisletta P., Dahle C.L., Bender A.R., Yang Y., Yuan P., et al. Regionalbrainshrinkageover two years: individual differences and effects of pro-inflammatory genetic polymorphisms. NeuroImage 2014, 103:334-348.
148. Petersen S., Saretzki G., von Zglinicki T. Preferential accumulation of single-stranded regions in telomeres of human fibroblasts. Exp. Cell Res. 1998, 239:152-160.
149. Piao M.J., Kim K.C., Zheng J., Yao C.W., Cha J.W., Kang H.K., et al. Gracilaria bursa-pastoris (gmelin) Silva extract attenuatesultravioletBradiation-induced oxidative stress in human keratinocytes. J. Environ. Pathol. Toxicol. Oncol. 2014, 33(1):33-43.
150. Pomara N., Bruno D., Sarreal A.S., Hernando R.T., Nierenberg J., Petkova E., et al. Lower CSF amyloid beta peptides and higherF2-isoprostanesin cognitively intact elderly individuals with majordepressive disorder. Am. J. Psychiatry 2012, 169(5):523-530.
151. Potter G.G., McQuoid D.R., Steffens D.C. Appetiteloss and neurocognitivedeficitsin late-lifedepression. Int. J. Geriatr. Psychiatry 2014, 30(6):647-654.
152. Puterman E., Epel E.S., Lin J., Blackburn E.H., Gross J.J., Whooley M.A., et al. Multisystem resiliency moderates the major depression-telomere length association: findings from the heart and soul study. Brain Behav. Immun. 2013, 33:65-73.
153. Radak Z., Chung H.Y., Goto S. Systemic adaptation to oxidative challenge induced by regular exercise. Free Radic. Biol. Med. 2008, 44:153-159.
154. Raison C.L., Rutherford R.E., Woolwine B.J., Shuo C., Schettler P., Drake D.F., et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013, 70(1):31-41.
155. Réus G.Z., Fries G.R., Stertz L., Badawy M., Passos I.C., Barichello T., et al. The role ofinflammationand microglial activation in the pathophysiology of psychiatric disorders. Neuroscience 2015, 300:141-154.
156. Rimer J., Dwan K., Lawlor D.A., Greig C.A., McMurdo M., Morley W., et al. Exercise for depression. Cochrane Database Syst. Rev. 2012, 7:CD004366.
157. Rizvi S.I., Maurya P.K. Alterations in antioxidant enzymes during aging in humans. Mol. Biotechnol. 2007, 37(1):58-61.
158. Rizvi S.I., Maurya P.K. L-cysteine influx in erythrocytes as a function of human age. Rejuvenation Res. 2008, 11(3):661-665.
159. RizviSI, Jha R, MauryaPK. Erythrocyte plasma membrane redox system in human aging. Rejuvenation Res. 2006; 9(4):470-4.
160. Rizvi S.I., Maurya P.K. Markers of oxidative stress in erythrocytes during aging in humans. Ann. N. Y. AcadSci 2007, 1100:373-382.
161. Rogina B., Reenan R.A., Nilsen S.P., Helfand S.L. Extended life-span conferred by cotransporter gene mutations in drosophila. Science 2000, 290(5499):2137-2140.
162. Rojas P., Serrano-García N., Medina-Campos O.N., Pedraza-Chaverri J., Ogren S.O., Rojas C. Antidepressant-like effect of a Ginkgo biloba extract (EGb761) in the mouse forced swimming test: role of oxidative stress. Neurochem. Int. 2011, 59(5):628-636.
163. Romano A.D., Serviddio G., de Matthaeis A., Bellanti F., Vendemiale G. Oxidative stress and aging. J. Nephrol 2010, 23(Suppl. 15):S29-S36.
164. Rufer N., Brümmendorf T.H., Kolvraa S., Bischoff C., Christensen K., Wadsworth L., et al. Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. J. Exp. Med. 1999, 190(2):157-167.
165. Rybka J., Kedziora-Kornatowska K., Banaś-Lezańska P., Majsterek I., Carvalho L.A., Cattaneo A., et al. Interplay between the pro-oxidant and antioxidant systems and proinflammatory cytokine levels, in relation to iron metabolism and the erythron in depression. Free Radic. Biol. Med. 2013, 63:187-194.
166. Salmina A.B., Komleva Y.K., Kuvacheva N.V., Lopatina O.L., Pozhilenkova E.A., Gorina Y.V., et al. Inflammation and brainaging. Vestn. Ross. Akad. Med. Nauk 2015, 1:17-25.
167. Scandalios J.G. Oxidative stress: molecular perception and transduction of signals triggering antioxidant gene defenses. Braz. J. Med. Biol. Res. 2005, 38(7):995-1014.
168. Scapagnini G., Davinelli S., Drago F., De Lorenzo A., Oriani G. Antioxidants as antidepressants: fact or fiction?. CNS Drugs 2012, 26(6):477-490.
169. Schairer D.O., Chouake J.S., Kutner A.J., Makdisi J., Nosanchuk J.D. FriedmanAJ. Evaluation of the antibiotic properties ofglutathione. J. Drugs Dermatol. 2013, 12(11):1272-1277.
170. Scheuing L., Chiu C.T., Liao H.M., Chuang D.M. Antidepressantmechanism of ketamine: perspective from preclinical studies. Front. Neurosci. 2015, 9:249.
171. Schiepers O.J., Wichers M.C., Maes M. Cytokinesandmajor depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2005, 29(2):201-217.
172. Schutte N.S., Malouff J.M. The association between depression and leukocyte telomere length: a meta-analysis. Depress. Anxiety 2015, 32(4):229-238.
173. Selley M.L. Increased (E)-4-hydroxy-2-nonenaland asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with majordepression. J. Affect. Disord. 2004, 80(2-3):249-256.
174. Sexton C.E., Mackay C.E., Ebmeier K.P. A systematic review of diffusion tensor imaging studies in affective disorders. Biol. Psychiatry 2009, 66:814-823.
175. Shazia Q., Mohammad Z.H., Rahman T., Shekhar H.U. Correlation of oxidative stress with serum trace element levels and antioxidante enzyme status in beta thalassemia major patients: a review of the literarture. Anemia 2012, 2012:270923.
176. Simon N.M., Walton Z.E., Bui E., Prescott J., Hoge E., Keshaviah A., et al. Telomere length and telomerase in a well-characterized sample of individuals with major depressive disorder compared to controls. Psychoneuroendocrinology 2015, 58:9-22.
177. Simon N.M., Smoller J.W., McNamara K.L., Maser R.S., Zalta A.K., Pollack M.H., et al. Telomereshorteningandmooddisorders: preliminarysupportforachronicstressmodelofacceleratedaging. Biol. Psychiatry 2006, 60(5):432-435.
178. Siwek M., Szewczyk B., Dudek D., Styczeń K., Sowa-Kućma M., Młyniec K., et al. Zincas amarkerofaffective disorders. Pharmacol. Rep. 2013, 65(6):1512-1518.
179. Siwek M., Dudek D., Schlegel-Zawadzka M., Morawska A., Piekoszewski W., Opoka W., et al. Serum zinc level in depressed patients during zinc supplementation of imipramine treatment. J. Affect. Disord. 2010, 126(3):447-452.
180. Soczynska J.K., Mansur R.B., Brietzke E., Swardfager W., Kennedy S.H., Woldeyohannes H.O., et al. Novel therapeutic targets in depression: minocycline as a candidate treatment. Behav. Brain Res. 2012, 235(2):302-317.
181. Soto M.E., Soria-Castro E., Lans V.G., Ontiveros E.M., Mejía B.I., Hernandez H.J., et al. Analysis ofoxidative stressenzymes andstructuraland functionalproteinson human aortic tissue from different aortopathies. Oxidative Med. Cell. Longev. 2014, 2014:760694.
182. Spiteller G. Lipid peroxidation in aging and age-dependent diseases. Exp. Gerontol. 2001, 36(9):1425-1457.
183. Stefanescu C., Ciobica A. The relevance of oxidative stress status in first episode and recurrentdepression. J. Affect. Disord. 2012, 143(1-3):34-38.
184. Stephens T. Physical activity and mental health in the United States and Canada: evidence from four population surveys. Prev. Med. 1988, 17:35-47.
185. Stief T.W. The physiology and pharmacology of singlet oxygen. Med. Hypotheses 2003, 60(4):567-572.
186. Stordal K.I., Lundervold A.J., Mykletun A., Asbjørnsen A., Biringer E., Egeland J., et al. Frequency and characteristics of recurrent major depressed patients with unimpaired executive functions. World J. Biol. Psychiatry 2005, 6(1):36-44.
187. Suthammarak W., Somerlot B.H., Opheim E., Sedensky M., Morgan P.G. Novel interactions between mitochondrial superoxide dismutases and the electron transport chain. AgingCell 2013, 12(6):1132-1140.
188. Swardfager W., Herrmann N., Mazereeuw G., Goldberger K., Harimoto T., Lanctôt K.L. Zincindepression: ameta-analysis. Biol. Psychiatry 2013, 74(12):872-878.
189. Szebeni A., Szebeni K., DiPeri T., Chandley M.J., Crawford J.D., Stockmeier C.A., et al. Shortened telomere length in white matter oligodendrocytes in major depression: potential role of oxidative stress. Int. J. Neuropsychopharmacol. 2014, 17(10):1579-1589.
190. Takeda A. Movement of zinc and its functional significance in the brain. Brain Res. Brain Res. Rev. 2000, 34(3):137-148.
191. Talarowska M., Gałecki P., Maes M., Gardner A., Chamielec M., Orzechowska A., et al. Malondialdehydeplasma concentration correlates with declarative and working memory in patients with recurrentdepressive disorder. Mol. Biol. Rep. 2012, 39(5):5359-5366.
192. Talarowska M., Orzechowska A., Szemraj J., Su K.P., Maes M., Gałecki P. Manganesesuperoxide dismutasegene expression and cognitive functions in recurrentdepressive disorder. Neuropsychobiology 2014, 70(1):23-28.
193. Targum S.D., Wedel P.C., Fava M. Changes in cognitive symptoms after a buspirone-melatonin combination treatment for major depressive disorder. J. Psychiatr. Res. 2015, 10.1016/j.jpsychires.2015.04.024.
194. Teychenne M., Ball K., Salmon J. Sedentary behavior and depression among adults: a review. Int J. Behav. Med. 2010, 17:246-254.
195. Uher R. Gene-environment interactions in severe mental illness. Front. Psychiatry 2014, 5:48.
196. Vallance J.K., Winkler E.A., Gardiner P.A., Healy G.N., Lynch B.M., Owen N. Associations of objectively-assessed physical activity and sedentary time with depression: NHANES (2005-2006). Prev. Med. 2011, 53:284-288.
197. Verhoeven J.E., Révész D., Epel E.S., Lin J., Wolkowitz O.M., Penninx B.W., et al. Of sound mind and body: depression, disease, and accelerated agingOf sound mind and body: depression, disease, and accelerated agingMajordepressive disorderandacceleratedcellularaging: results from a large psychiatric cohort study. Mol. Psychiatry 2014, 19(8):895-901.
198. Vin-Raviv N., Akinyemiju T.F., Galea S., Bovbjerg D.H. Depressionand anxiety disorders among hospitalized women with breastcancer. PLoS One 2015, 10(6):e0129169.
199. von Zglinicki T., Serra V., Lorenz M., Saretzki G., Lenzen-Grossimlighaus R., Gessner R., et al. Short telomeres in patients with vascular dementia: an indicator of low antioxidative capacity and a possible risk factor?. Lab. Investig. 2000, 80:1739-1747.
200. von Zglinicki T. Oxidative stress shortens telomeres. Trends Biochem. Sci. 2002, 27(7):339-344.
201. Wayhs C.A., Tortato C., Mescka C.P., Pasquali M.A., Schnorr C.E., Nin M.S., et al. The association effect of insulin and clonazepam onoxidative stressin liver of an experimental animal model of diabetes anddepression. Pharm. Biol. 2013, 51(5):533-538.
202. Weisiger R.A., Fridovich I. Superoxide dismutase. Organelle specificity. J. Biol Chem. 1973, 248(10):3582-3592.
203. White J., Zaninotto P., Walters K., Kivimäki M., Demakakos P., Shankar A., et al. Severity ofdepressivesymptoms as a predictor ofmortality: the English longitudinal study of ageing. Psychol. Med. 2015, 4:1-9.
204. Wiener C., Rassier G.T., Kaster M.P., Jansen K., Pinheiro R.T., Klamt F., et al. Gender-based differences in oxidative stress parameters do not underlie the differences in mood disorders susceptibility between sexes. Eur. Psychiatry 2014, 29(1):58-63.
205. Wikgren M., Maripuu M., Karlsson T., Nordfjäll K., Bergdahl J., Hultdin J., et al. Short telomeres in depression and the general population are associated with a hypocortisolemic state. Biol. Psychiatry 2012, 71(4):294-300.
206. Wolkowitz O.M., Reus V.I., Mellon S.H. Ofsoundmindandbody: depression, disease, andacceleratedaging. Dialogues Clin. Neurosci. 2011, 13(1):25-39.
207. Wu G., Fang Y.Z., Yang S., Lupton J.R., Turner N.D. Glutathionemetabolism and its implications for health. J. Nutr. 2004, 134(3):489-492.
208. Xie Q., Peng S., Tao L., Ruan H., Yang Y., Li T.M., et al. E2F transcription factor 1 regulatescellularand organismal senescence by inhibiting forkhead boxOtranscription factors. J. Biol. Chem. 2014, 289(49):34205-34213.
209. Yamamoto Y., Gaynor R.B. Role of the NF-kappaB pathway in the pathogenesis of human disease states. Curr. Mol. Med. 2001, 1(3):287-296.
210. Zhu W.L., Shi H.S., Wei Y.M., Wang S.J., Sun C.Y., Ding Z.B., et al. Green tea polyphenols produce antidepressant-like effects in adult mice. Pharmacol. Res. Off. J Italian Pharmacol. Soc. 2012, 65(1):74-80.